Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti–EGFR Monoclonal Antibody Combination Sym004

Symphogen Opens US Operations in Princeton, New Jersey

Symphogen Appoints Jørgen Petersen as Chief Development Officer

Symphogen Appoints Adriann Sax Chief Business Officer

Symphogen and Origen Collaborate to Produce Transgenic Chicken for generation of Fully Human Antibody Therapeutics

Symphogen secures € 33 million financing to support clinical development of antibody products

Symphogen acquires Receptor BioLogix's technology

Symphogen and Meiji Seika Kaisha LTD. Achieve milestone in discovery collaboration for recombinant polyclonal antibody, SYM006

Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

Symphogen-Biovitrum Phase II Clinical Trial Initiated

Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics

Biovitrum and Symphogen Initiate a Second Clinical Study with a Novel Treatment of Hemolytic Diseases

Symphogen issued patent covering Symplex™ technology for antibody discovery

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody

Biovitrum og Symphogen har færdiggjort succesfyldt fase I klinisk forsøg med et rekombinant polyklonalt antistof

Symphogen IBC Sym003 Press release

Symphogen A/S kåret som Danmarks bedste biotekvirksomhed

Symphogen A/S awarded Best Danish Biotech Company 2007

Symphogen appoints Ian Nicholson to Board of Directors

Symphogen styrker bestyrelse

Symphogen Granted European Patent Covering Use of Polyclonal Antibodies for Allergy Indications

Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation

Symphogen og Biovitrum indleder kliniske studier af ny type lægemiddel

Symphogen receives 5 Million Euro investment from Gilde Healthcare Partners

Symphogen og Meiji indgår samarbejde

Symphogen and Meiji Kaisha enter agreement for recombinant polyclonal antibody product

Symphogen A/S styrker klinisk udvikling

Symphogen appoints Christian Meyer Vice President of Clinical Development and Dr. Henrik Rasmussen to Medical Advisory Board

Symphogen A/S får patent på Sympress™ teknologi til produktion af rekombinante polyklonale antistoffer

Symphogen Issued Patent Covering Sympress™ Technology for Manufacturing Rekombinant Polyclonal Antibodies

Symphogen to evaluate AttSite™ Recombinase for development of manufacturing cell lines

Symphogen appoints Dr Søren Bregenholt Vice President of Project Management

Symphoen udnævner Søren Bregenholt til Vice President of Project Management

Biovitrum and Symphogen Enter Co-development and Commercialization Agreement for Recombinant Polyclonal Antibodies for the treatment of certain blood disorders

Symphogen på vej mod nyt lægemiddel

Kapitaltilførsel på 154 millioner kroner til Symphogen til videre udvikling af rekombinante polyklonale antistoffer

Symphogen A/S and Cambridge Antibody Technology Sign Patent Licensing Agreement

Symphogens Success in Manufacturing Consistent Batches of Polyclonal Antibodies for Clinical Trials Attracts New USD 25 Million Investment